| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Pharmather Holdings Ltd: Pharmather signs distribution deal with Craft Health | 1 | Stockwatch | ||
| Do | PharmaTher Holdings Ltd.: PharmaTher Enters into Exclusive North American Distribution Agreement with Craft Health for CraftMake Pharmaceutical 3D Printing Platform | 233 | Newsfile | Agreement opens the U.S. and Canadian markets across all customer segments and lays the foundation for PharmaTher's personalized 503A products, FDA rare disease program, national emergency and medical... ► Artikel lesen | |
| 18.08. | Pharmather Holdings Ltd: Pharmather selects PD Labs for Personaliz3d system | 2 | Stockwatch | ||
| 12.08. | Pharmather Holdings Ltd: Pharmather launches Personaliz3D business model | 1 | Stockwatch | ||
| 11.08. | PharmaTher Holdings Ltd.: PharmaTher Establishes PERSONALIZ3D to Commercialize a Personalized Medicine Platform Combining Telehealth and Pharmaceutical 3D Printing | 850 | Newsfile | Toronto, Ontario--(Newsfile Corp. - August 11, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) (the "Company" or "PharmaTher"), a life sciences company focused on personalized medicines... ► Artikel lesen | |
| 04.08. | PharmaTher prüft 3D-Druck personalisierter Peptid-Arzneimittel | 1 | 3Druck.com | ||
| 30.07. | PharmaTher evaluating 3D printing for personalized peptide medicines | 1 | The Market Online Canada | ||
| 30.07. | Pharmather Holdings Ltd: Pharmather, Craft Health to develop peptides | 1 | Stockwatch | ||
| PHARMATHER Aktie jetzt für 0€ handeln | |||||
| 29.07. | PharmaTher Holdings Ltd.: PharmaTher Collaborates with Craft Health to Evaluate CraftMake GMP-Ready Pharmaceutical 3D Printing Platform for Personalized Peptides | 845 | Newsfile | Toronto, Ontario--(Newsfile Corp. - July 29, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a specialty pharmaceutical company focused on personalized... ► Artikel lesen | |
| 28.07. | Pharmather Holdings Ltd: Pharmather Holdings launches Personaliz3D Peptides | 1 | Stockwatch | ||
| 27.07. | PharmaTher Holdings Ltd.: PharmaTher Launches Personaliz3D Peptides to Advance Personalized Peptide Care Following Positive FDA Advisory Committee Recommendations | 792 | Newsfile | New division will address the limitations of traditional peptide compounding through 3D printing and AIPharmaTher plans to connect patients, physicians and qualified pharmacies through an integrated... ► Artikel lesen | |
| 22.07. | Pharmather Holdings Ltd: Pharmather pushes forward with ketamine platform | 2 | Stockwatch | ||
| 21.07. | PharmaTher partners with KetaMist developer for FDA approval push | 3 | Investing.com | ||
| 21.07. | PharmaTher kooperiert mit KetaMist-Entwickler zur Vorbereitung einer FDA-Zulassung | 2 | Investing.com Deutsch | ||
| 21.07. | PharmaTher Holdings Ltd.: PharmaTher Enters into Collaboration Agreement for KetaMist(R) to Advance Needle-Free Ketamine Treatment Toward FDA Approval | 541 | Newsfile | Collaboration combines more than 9,000 KetaMist patient treatments with PharmaTher's prior FDA-approved ketamine experiencePursuing an efficient FDA development pathway toward approval for treatment-resistant... ► Artikel lesen | |
| 15.07. | Pharmather Holdings Ltd: Pharmather sees movement in U.S. toward psychedelics | 2 | Stockwatch | ||
| 15.07. | PharmaTher Holdings Ltd.: PharmaTher Updates Strategy on Personalized Medicines for Peptides and Psychedelics | 306 | Newsfile | Toronto, Ontario--(Newsfile Corp. - July 15, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a specialty pharmaceutical company focused on personalized... ► Artikel lesen | |
| 28.05. | Pharmather Holdings Ltd: Pharmather to focus on Medbotx platform | 1 | Stockwatch | ||
| 27.05. | PharmaTher Holdings Ltd.: PharmaTher Evolves Platform Strategy with MEDBOTX Robotic 3D Printing for Personalized Medicines | 361 | Newsfile | MEDBOTX represents the evolution into a broader point-of-care manufacturing platform designed for personalized medicines, peptides and advanced dose formatsPotential U.S. peptide reclassification... ► Artikel lesen | |
| 13.05. | Pharmather Holdings Ltd: Pharmadrug, Pharmather to explore PD-001 for hantavirus | 3 | Stockwatch |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 44,940 | -1,01 % | 90 Milliarden US-Dollar bis 2030: Wie Bayer, Mesoblast und NurExone regenerative Medizin unterschiedlich entwickeln | ||
| MERCK KGAA | 136,90 | +1,82 % | Merck Aktie | Wichtige Durchschnittslinien durchbrochen | Analyse | ||
| NOVO NORDISK | 33,210 | -0,48 % | Novo Nordisk gerät trotz GLP-1 unter Druck - warum Eli Lilly und Co. schon Milliarden in neue Plattformen investieren | ||
| ETON PHARMACEUTICALS | 55,42 | 0,00 % | Eton Pharmaceuticals, Inc. - 8-K, Current Report | ||
| SANOFI | 71,08 | -0,03 % | Laufende Fusionskontrollverfahren: Sanofi, Paris/FR; Erwerb eines Minderheitsanteils an der Cheplapharm SE (Gemeinschaftsunternehmen mit der Braun Invest Holding GmbH, Greifswald) | Datum der Anmeldung:24.09.2026Aktenzeichen:B3-102/26Unternehmen:Sanofi, Paris/FR; Erwerb eines Minderheitsanteils an der Cheplapharm SE (Gemeinschaftsunternehmen mit der Braun Invest Holding GmbH, Greifswald)Produktmärkte:Arzneimittel... ► Artikel lesen | |
| GENERATE BIOMEDICINES | 13,685 | -0,04 % | Generate Biomedicines, Inc.: Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of 'Armored' CAR T Therapy for Ovarian Cancer | Engineered with AI to optimize T-cell function in solid tumors, GB-5267 is the first next-generation cell therapy for ovarian cancer to enter clinical trials First patient treated in new clinical... ► Artikel lesen | |
| SEAPORT THERAPEUTICS | 18,420 | 0,00 % | Seaport Therapeutics Prices Upsized IPO Of 14.16 Mln Shares At $18 Each | WASHINGTON (dpa-AFX) - Seaport Therapeutics, Inc. (SPTX) said it has priced its upsized initial public offering of 14.16 shares at $18 per share, at the top of the target range. The company... ► Artikel lesen | |
| PFIZER | 24,735 | +0,18 % | Litfulo and tilrekimig data bolster Pfizer's immunology plans | ||
| LB PHARMACEUTICALS | 37,080 | +0,24 % | Needham initiates LB Pharmaceuticals stock with buy rating | ||
| ELI LILLY | 1.019,20 | +0,33 % | Eli Lilly's Jaypirca gains additional indication for untreated leukemia, lymphoma | ||
| BIOHAVEN | 12,870 | 0,00 % | Biohaven Ltd.: Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026 | Oral presentation selected: Phase 1 findings from the ongoing BHV1530-101 study will be featured in an oral presentation at the 38th EORTC-NCI-AACR Symposium on... ► Artikel lesen | |
| SCHOTT PHARMA | 24,550 | +0,82 % | Aktien Frankfurt: Dax macht Verluste wett - Ölpreis und Anleiherenditen im Fokus | FRANKFURT (dpa-AFX) - Der deutsche Aktienmarkt hat sich am Dienstagnachmittag von seinen Anfangsverlusten vollständig erholt. Eine leichte Entspannung bei den Ölpreisen und bei den Anleiherenditen... ► Artikel lesen | |
| NOVARTIS | 124,98 | -0,14 % | CH-Verlauf: Fester dank Novartis und Nestlé, Roche fallen ab | Zürich - Der Schweizer Aktienmarkt ist mit Schwung in die neue Woche gestartet und hat die Marke bei 14'000 klar zurückerobert. In der Folge konnte er indes dieses Niveau nicht ganz halten. Gestützt... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 4,555 | +0,11 % | Aquestive appoints Rich Daly to board of directors | ||
| GILEAD SCIENCES | 128,68 | +0,09 % | Assembly Biosciences: Herpes-Countdown mit Gilead |